• The Schall Law Firm has begun investigating Doximity, Inc. over potential securities law violations after the company’s May 13, 2026 results missed revenue expectations and highlighted near-term margin pressure from AI investments.
• This combination of weaker-than-anticipated performance and legal scrutiny raises fresh questions about how Doximity is communicating the financial impact of its AI roadmap to investors.
• We’ll now examine how concerns about margin pressure from AI spending could influence Doximity’s previously AI-focused investment narrative.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Doximity Investment Narrative Recap

The core Doximity thesis is about owning a digital workflow and advertising platform that sits at the center of U.S. physicians’ daily routines. The recent revenue miss, margin pressure from AI spending, and fresh legal scrutiny may weigh on the near term, but the bigger question for the stock now is whether AI investments can still support profitable growth while heavy stock-based compensation and operating costs are constraining margins.

The most relevant recent update is Doximity’s May 13 guidance for FY2027 revenue of US$664 million to US$676 million, issued alongside the disappointing Q4 FY2026 results. That outlook now sits under a cloud, given the 23% share price drop and the investigation into past disclosures. How management updates this guidance, and explains the payback from AI tools like Scribe and Ask, could shape confidence in the company’s next leg of growth.

Yet behind the AI story, investors should also be aware of how rising compliance costs and tighter digital privacy rules could affect Doximity’s core ad business...

Doximity's narrative projects $769.1 million revenue and $212.2 million earnings by 2029. This requires 6.0% yearly revenue growth and about a $16 million earnings increase from $196.1 million today.

Uncover how Doximity's forecasts yield a $25.15 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Before this selloff, the most cautious analysts were already modeling revenue of about US$734 million and earnings of roughly US$167 million by 2029, which reflects a much weaker margin profile than the consensus and highlights how differently you and other shareholders might view the impact of heavier AI spending and competition once this latest news is fully absorbed.

Explore 4 other fair value estimates on Doximity - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Doximity research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.